Third-generation tyrosine kinase inhibitors and beyond.

Abstract excerpt

Imatinib is considered standard frontline therapy for the management of patients with chronic myeloid leukemia (CML). However, it is estimated that approximately one third of patients will fail imatinib therapy. The recommended therapeutic approach for those patients is the use of a second-generation tyrosine kinase inhibitor (TKI) such as nilotinib or dasatinib. With these agents, approximately 50% of patients...

Topics

Join the communities discussing this publication.

• Benzamides
• Cytogenetic Analysis
• Fusion Proteins, bcr-abl
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive